Stay updated on Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the unavailable study record.
    Difference
    1%
    Check dated 2026-10-24T14:41:54.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s site revision indicator changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-17T14:34:17.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T15:30:09.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content, resulting in an inaccessible error screen for the trial details.
    Difference
    18%
    Check dated 2026-09-19T22:02:55.000Z thumbnail image
  5. Check
    60 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.5 to v3.6.6. This represents a minor update to the site's underlying version.
    Difference
    0.1%
    Check dated 2026-08-29T19:13:15.000Z thumbnail image
  6. Check
    81 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4. This indicates a minor site update rather than changes to study data.
    Difference
    0.0%
    Check dated 2026-08-08T22:42:45.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.